The recent publication by Mollaoglu et al confirmed MYC as a driver of response to alisertib by showing that over-expression of MYC in a conditional genetically engineered mouse model (GEMM) of SCLC with Myc overexpression increased sensitivity to alisertib [23]. The gene discussed is MYC; the disease is small cell lung carcinoma.